The Emerging Parkinson's Disease Oxylipin‐Ome
Advanced Science · 2026-06 · 13 (33)
DOI: 10.1002/advs.202522997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 22.04.2026. Verfasst von Julia C Kelliher und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, U…. Hauptthemen laut MEDLINE: Parkinson Disease, Oxylipins, Fatty Acids. Die Arbeit nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ellison Foundation of Boston (SF), NIH HHS, The Silverstein Foundation.
Abstract (Originalsprache)
Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)‐opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction. FA dysfunction can disrupt alpha‐synuclein (αS)‐membrane interactions, altering αS localization, conformation, and aggregation. Correcting FA dyshomeostasis rescues PD‐associated αS phenotypes and is a promising strategy for disease‐modifying therapeutics. Herein, we consider the impact of PD FA dyshomeostasis in modifying the bioactive oxylipin‐ome. Oxylipin metabolism is complex, and the role of oxylipins in PD is not yet fully determined. This perspective considers PD‐associated differences oxylipin profiles, oxylipin precursor polyunsaturated fatty acids (PUFAs), and oxylipin biosynthetic enzymes in human PD studies to explore a potential PD oxylipin‐ome signature. Founded on disrupted oxylipin and oxylipin precursor PUFA abundance, higher PUFA intake reducing PD risk and progression, and the association between cyclooxygenase (COX) inhibition and lower PD incidence, we posit that the oxylipin‐ome plays a role in PD. Oxylipin metabolism may be a novel target for PD biomarkers and disease‐modifying therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Julia C Kelliher, Saranna Fanning
Förderung
- Ellison Foundation of Boston (SF)
- NIH HHS
- The Silverstein Foundation
- The Michael J. Fox Foundation (SF)
- National Science Foundation
Zitieren
APA
Kelliher, J. C., & Fanning, S. (2026). The Emerging Parkinson's Disease Oxylipin‐Ome. Advanced Science, 13(33). https://doi.org/10.1002/advs.202522997
Vancouver
Kelliher JC, Fanning S. The Emerging Parkinson's Disease Oxylipin‐Ome. Advanced Science. 2026;13(33). doi:10.1002/advs.202522997
BibTeX
@article{Kelliher2026,
author = {Kelliher, Julia C and Fanning, Saranna},
title = {The Emerging Parkinson's Disease Oxylipin‐Ome},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {33},
doi = {10.1002/advs.202522997}
}
EUVIMED